With validations of experiments and HCC patients in multiple cohorts, we provided lines of evidence that TK1, TYMS and DTYMK the catalytic RLEs in pyrimidine biosynthesis play critical roles in cancer stemness and serve as potential therapeutic targets in poorly-differentiated HCC. This evidence concerns the gene DTYMK and hepatocellular carcinoma.